Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9277030 | 0.82 | CES2 (0.52) | CES2CES1LMNAKEAP1NFE2L2 | |
| SCHEMBL21495114 | 0.82 | CES2 (0.52) | CES2CES1LMNAKEAP1NFE2L2 | |
| SCHEMBL4018555 | 0.82 | CES2 (0.52) | CES2CES1CNR2POLB | |
| SCHEMBL234580 | 0.80 | CES2 (0.76) | CES2CES1LMNACYP2C19 | |
| SCHEMBL5899350 | 0.80 | CES2 (0.76) | CES2CES1LMNACYP2C19 | |
| Benzene SCHEMBL28201061 | 0.80 | CES2 (0.76) | CES2CES1LMNACYP2C19 | |
| SCHEMBL604040 | 0.80 | CES2 (0.76) | CES2CES1LMNACYP2C19 | |
| SCHEMBL9285788 | 0.80 | ALDH1A1 (0.43) | CES2CES1LMNAKEAP1NFE2L2 | |
| SCHEMBL8763327 | 0.80 | ALOX5 (0.48) | CES2CES1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19937907 | 0.80 | CES2 (0.40) | CES2CES1LMNAKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240027902-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-11720020-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11720020-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-1874298-A4 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV PHARMACEUTICAL INC (US) | 2009-08-05 | — | — | EP | disclosed |
| CN-101272684-A | Methods and compositions for the treatment of neuropathies and related disorders | DOV PHARMACEUTICAL INC (US) | 2008-09-24 | — | — | CN | disclosed |
| EP-1915148-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV Pharmaceutical, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1874298-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV Pharmaceutical Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006096810-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2006-09-14 | — | — | WO | disclosed |
| US-4307232-A | Preparation of dialkyl- and diarylphosphonoalkanoic acids and substituted acrylic acids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | CES2 243/4885CES1 630/4885LMNA 1263/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | CES2 165/4885CES1 370/4885LMNA 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.